Christoph Westphal and the crew at Novartis-backed TScan aren't waiting to take their preclinical TCR pitch to Nasdaq
Just 3 months ago, TScan CEO David Southwell told Endpoints News’ Nicole DeFeudis that it was likely the oncology startup would go public at some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
